Of note, the use of the dihydroorotate dehydrogenase inhibitor Vidofludimus (SC12267) which attenuates IL17A/F and IFNγ, is also in clinical trials and it remains to be seen whether it has the potential of becoming useful treatment modalities in IBD patients (34). The gene discussed is IL17A; the disease is inflammatory bowel disease.